EyePoint Pharmaceuticals appoints new SVP of regulatory affairs & quality: 3 things to know

Written by Rachel Popa | August 15, 2018 | Print  |

EyePoint Pharmaceuticals appointed John Weet, PhD, as its new senior vice president of regulatory affairs and quality.

Here are three things to know about Dr. Weet:

1. Dr. Weet has over 40 years of experience in regulatory affairs, including oversight of U.S. Food and Drug Administration relations in the area of ocular disease.

2. Previously, he served as the vice president of regulatory affairs and quality assurance at Collegium Pharmaceutical, and as the vice president of global regulatory affairs at Bausch + Lomb.

3. At Bausch + Lomb, Dr. Weet worked on the regulatory submission for Besivance, a drug for the treatment of bacterial conjunctivitis.

More articles on supply chain:
Supply chain tip of the day: Take advantage of the cloud
How ASCs can be held liable for 3D medical devices — And 5 strategies to avoid risk
Supply chain tip of the day: Use mobile apps in the ordering process

 

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.